Idelalisib Completed Phase 2 Trials for Mantle Cell Lymphoma (MCL) / Indolent Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01796470Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies